Roivant Sciences Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ROIV | ARGX | IMVT | GMAB | IDYA | VRDN | |
|---|---|---|---|---|---|---|
| Market cap | 24.99B | 51.08B | 6.09B | 22.98B | 3.48B | 2.07B |
| P/E (TTM) | — | 31.0 | — | 29.4 | — | — |
| Forward P/E | -20.1 | 22.8 | -10.7 | 24.5 | -9.0 | -6.7 |
| Price/book | 5.9 | 150.9 | 8.3 | 3.7 | 2.9 | 3.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +118.63% | −0.08% | +75.62% | +13.43% | +34.89% | −12.68% |
| Today | −2.40% | −1.54% | −3.25% | +0.81% | −0.14% | −1.93% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ROIV news ›Reviewing Janux Therapeutics (NASDAQ:JANX) & Roivant Sciences (NASDAQ:ROIV)
Posted by Tristan Rich on Oct 11th, 2026 Janux Therapeutics (NASDAQ:JANX – Get Free Report) and Roivant Sciences (NASDAQ:ROIV – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two…
Roivant Sciences Ltd. (NASDAQ:ROIV) Stock Has Average Target Price of $45.64
Posted by Sarita Garza on Oct 10th, 2026 Check Out Our Latest Research Report on ROIV Roivant Sciences Ltd. (NASDAQ:ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with…
Roivant Sciences director sells 17,750 shares
Roivant Sciences (ROIV) director exercises $4.46 options and sells 17,750 shares. Stock Titan - [Form 4] Roivant Sciences Ltd. Insider Trading Activity Roivant Sciences director sells 17,750 shares The director's two sales were made under…
Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya
Roivant Sciences has always been a little different from traditional drugmakers with its hub-and-spoke subsidiary model and an overarching hedge fund mentality. And now that the company has embarked on a new drug launch solo, CEO Matt…
Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roivant Sciences (ROIV) and Johnson & Johnson (JNJ). Bernstein analyst Eve Burstein maintained a Buy rating on Roivant Sciences yesterday and…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
themarketsdaily.com2
-
biospace.com1
-
stocktitan.net1
-
theglobeandmail.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.